A big pharmaceutical acquisition sees Teva Pharmaceuticals Industries Ltd. (TEVA) has annuounced an agreement to acquire Cephalon Inc. (CEPH) in a deal worth $6.8 billion. This is seen as a move to build its branded pharmaceuticals business and reach its financial targets set for 2015.
Shares of both companies rose on premarket trading with Cephalon stocks rising by 5.5% to $81.25 and Teva’s American depository shares rising by 3.4% to $47.30.
In an investor’s meeting in early 2011, Teva announced to investors it was on the hunt for new acquisitions and was considering several options.
The deal between Teva and Cephalon now means Canadian pharmaceuticals giant Valeant Pharmaceuticals cannot take over Cephalon. Valeant made a hostile $5.7 billion bid for Cephalon which was rejected. Valeant’s stocks dropped by 7.9% to $48.50 in premarket trading in New York.
Teva officials announed on Monday the deal with Cephalon will instantly add to the company’s adjusted earnings. The deal is expected to boost profits within a year of closing the deal.
In February, Teva — which is the largest manufacturers of generic drugs in the world — announced it needed to add an additional $4 billion to $5 billion in revenue per anum in order to meet its 2015 target of $31 billion. In March this year, Teva and Procter $ Gamble announced a venture deal which expands Teva’s over-the-counter medication business beyond the shores of the North America.
The last big acquisition by Teva was in 2008 when the company bought Barr Pharmaceuticals for $7.46 billion.





